Evidence map›Paper›PMID 38293025›Full record

ArticlebioRxiv : the preprint server for biology2024

Glycan-costumed virus-like particles promote type 1 anti-tumor immunity.

Valerie Lensch, Adele Gabba, Robert Hincapie, Sachin H Bhagchandani, Ankit Basak, Mohammad Murshid Alam, Darrell J Irvine, Alex K Shalek, Jeremiah A Johnson, M G Finn and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Valerie LenschDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-0371-2866
Adele GabbaDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-8240-6482
Robert HincapieSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0001-7358-4543
Sachin H BhagchandaniDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-4410-5800
Ankit BasakDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-9240-7147
Mohammad Murshid AlamDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-5646-3309
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-8637-1405
Alex K ShalekDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-5670-8778
Jeremiah A JohnsonDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-9157-6491
M G FinnSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0001-8247-3108
Laura L KiesslingDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-6829-1500
Massachusetts Institute of Technology · USBroad Institute · USGeorgia Institute of Technology · USHoward Hughes Medical Institute · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Synthetic Ligands for Modulating Immune Cell ResponsesR01AI055258 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KIESSLING, LAURA L · 2003 to 2024
$7.8M
Organic nanoparticles for dual MRI-guided therapeutic selection and ovarian cancer drug deliveryR01CA220468 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jeremiah Allen Johnson · 2017 to 2026
$4.9M
Lymph node-targeted multistage chemoimmunotherapy for lymphomaR01CA247484 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI FINN, M.G., THOMAS, SUSAN NAPIER · 2020 to 2024
$2.6M
Toward safe, systemic immunotherapies for treatment of metastatic disease: Developing dendritic cell-biased immunomodulators with precise control over magnitude and timing of immune stimulationF99CA264404 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BHAGCHANDANI, SACHIN · 2021 to 2022
$93k
NCI NIH HHS F99 CA264404NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA220468NCI NIH HHS R01 CA247484NIAID NIH HHS R01 AI055258
6 · The paper itself

Abstract

Cancer vaccine development is inhibited by a lack of strategies for directing dendritic cell (DC) induction of effective tumor-specific cellular immunity. Pathogen engagement of DC lectins and toll-like receptors (TLRs) shapes immunity by directing T cell function. Strategies to activate specific DC signaling pathways via targeted receptor engagement are crucial to unlocking type 1 cellular immunity. Here, we engineered a glycan-costumed virus-like particle (VLP) vaccine that delivers programmable peptide antigens to induce tumor-specific cellular immunity

Identifiers

PMID38293025
PMCPMC10827186
OpenAlexW4391006286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.